Corporate Presentation
Cautionary Note Regarding Forward Looking Statement
This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as
"anticipate," "expect," "plan," "may," "will," and similar expressions (as well as other words or expressions referencing future events or circumstances)
are intended to identify forward-looking statements. All statements other than statements of historical fact in this presentation are forward looking
including, but not limited to, statements regarding future operations, financial results and the financial condition of Exicure, Inc. ("Exicure" or the
"Company"); the Company's cash runway; the Company's business strategy, including the development of product candidates based on its proprietary
SNA technology; the initiation, timing, progress, scope and results of the Company's preclinical studies, clinical trials and research and development
programs; its plans for development of cavrotolimod (AST-008), including its Phase 1b/2 clinical trial; the timing, availability and presentation of
preclinical, clinical and regulatory developments; the potential benefits of the Company's product candidates; the development and the commercial
potential, growth potential and market opportunity for the Company's product candidates, if approved, and the drivers, timing, impact and results
thereof; potential and future results of current and planned collaborations; and the timing or likelihood of regulatory filings and approvals. Forward-
looking statements are based on management's current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of
future performance. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors,
including, without limitation: the risk that the COVID-19 pandemic and the associated containment efforts may have a material adverse impact on the
Company's business, operations and financial results; the Company's preclinical or clinical programs do not advance or result in approved products on a
timely or cost effective basis or at all; unexpected safety or efficacy data observed during preclinical or clinical studies; the failure of the data from the
Company's preclinical trials to be indicative in human trials; clinical site activation rates or clinical trial enrollment rates that are lower than expected;
the cost, timing and results of clinical trials; changes in the regulatory environment; unexpected litigation or other disputes; the ability of the Company
to protect its intellectual property rights; and the actual funding required to develop and commercialize the Company's product candidates and operate
the Company. For a discussion of other risks and uncertainties, and other important factors, any of which could cause the Company's actual results to
differ from those contained in the forward-looking statements, see the section titled "Risk Factors" in the Company's most recent Form 10-K, as well as
discussions of potential risks, uncertainties, and other important factors in its subsequent filings with the Securities and Exchange Commission. The
forward-looking statements in this presentation speak only as of the date of this presentation, and the Company undertakes no obligation to update
these forward-looking statements, unless required by law.
exicure | 2View entire presentation